SurModics expands with Brookwood buy:
This article was originally published in Clinica
Drug delivery technology provider SurModics has acquired Brookwood Pharmaceuticals, a subsidiary of the Southern Research Institute, for $40m in cash. The deal, which could rise by a further $22m pending the achievement of specific milestones, sees SurModics (Eden Prairie, Minnesota) gain proprietary polymer-based technologies and broaden its range of markets to include oncology, ophthalmology and orthopaedics. Brookwood, which will retain its operating facilities in Birmingham, Alabama, recorded $12.7m in revenues in 2006, and is profitable and cash flow positive, so is expected to be accretive to SurModics' fiscal 2008 earnings.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.